Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis

Breast

Volumn 20, Issue 6, 2011, Pages 485-490

  Valachis, Antonis ^a,b   Mauri, Davide ^c   Polyzos, Nikolaos P ^c   Chlouverakis, Grigoris ^d   Mavroudis, Dimitrios ^a   Georgoulias, Vassilios ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Central Hospital of Eskilstuna   (Sweden)

^c Oncology and Obstetrics and Gynaecology   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Breast cancer; Her2; Meta analysis; Neoadjuvant; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; FEBRILE NEUTROPENIA; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NEUTROPENIA; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 82955187799     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.06.009     Document Type: Review

References (28)

1. Schwartz G.F., Hortobagyi G.N., Masood S., Palazzo J., Holland R., Page D. Consensus Conference Committee. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA. Hum Pathol 2004, 35:781-784.
2. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:188-194.
3. Chia S., Swain S.M., Byrd D.R., Mankoff D.A. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008, 26:786-790.
4. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
5. Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
6. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
7. Viani G.A., Afonso S.L., Stefano E.J., De Fendi L.I., Soares F.V. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007, 7:153.
8. Harris C.A., Ward R.L., Dobbins T.A., Drew A.K., Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol 2010 Nov 30.
9. Dawood S., Broglio K., Buzdar A.U., Hortobagyi G.N., Giordano S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010, 28:92-98.
10. Tagliabue E., Agresti R., Carcangiu M.L., Ghirelli C., Morelli D., Campiglio M., et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003, 362:527-533.
11. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
12. Chang H.R. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010, 116:2856-2867.
13. Steger G., Greil R., Jakesz R., Lang A., Mlineritsch B., Melbinger-Zeinitzer E., et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Res 2009, 69(24 Suppl.). Abstract nr 1081.
14. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
15. Pierga J.Y., Delaloge S., Espié M., Brain E., Sigal-Zafrani B., Mathieu M.C., et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 2010, 122:429-437.
16. Chang H.R., Slamon D., Prati R., Glaspy J., Pegram M., Kass F.C., et al. A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: response and cardiotoxicity. J Clin Oncol 2006, 24(18S):10515.
17. Chang H.R., Slamon D., Gornbein J.A., Chung D. Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C). J Clin Oncol 2008, 26. (May 20 Suppl.; abstr 604).
18. Buzdar A.U., Valero V., Ibrahim N.K., Francis D., Broglio K.R., Theriault R.L., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007, 13:228-233.
19. Lazaridis G., Pentheroudakis G., Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol 2008 Apr, 66(1):31-41.
20. Untch M., Rezai M., Loibl S., Fasching P.A., Huober J., Tesch H., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010 Apr 20, 28(12):2024-2031.
21. von Minckwitz G., Untch M., Nüesch E., Loibl S., Kaufmann M., Kümmel S., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011, 125:145-156.
22. Liao N., Zhang G.C., Li X.R., Yao M., Wang K., Zu J. Efficacy and safety assessment of neoadjuvant paclitaxel and trastuzumab in Chinese women with Her-2 positive operable breast cancer. Zhonghua Zhong Liu Za Zhi 2010, 32:544-547.
23. Carlson R.W., Allred D.C., Anderson B.O., Burstein H.J., Carter W.B., Edge S.B., et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009, 7:122-192.
24. Russell S.D., Blackwell K.L., Lawrence J., Pippen J.E., Roe M.T., Wood F., et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010, 28:3416-3421.
25. Procter M., Suter T.M., de Azambuja E., Dafni U., van Dooren V., Muehlbauer S., et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010, 28:3422-3428.
26. Kaufmann M., Hortobagyi G.N., Goldhirsch A., Scholl S., Makris A., Valagussa P., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006, 24:1940-1949.
27. Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B. Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001, 30:96-102.
28. Frasci G., D'Aiuto G., Comella P., D'Aiuto M., Di Bonito M., Ruffolo P., et al. Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Ann Oncol 2010, 21:707-716.